IL-1 antagonists;IL-1-antagonisten

Zeitschrift fur Rheumatologie

Volumn 69, Issue 7, 2010, Pages 581-593

  Kotter I ^a   Horneff, G ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Asklepios Klinik Sankt Augustin   (Germany)

Author keywords

Anakinra; Autoinflammatory syndrome; Canakinumab; Rilonacept; TNF blockers

Indexed keywords

CANAKINUMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT ONSET STILL DISEASE; AUTOINFLAMMATORY DISEASE; DRUG APPROVAL; DRUG EFFICACY; JUVENILE RHEUMATOID ARTHRITIS; PROTEIN BINDING; REVIEW; RHEUMATOID ARTHRITIS;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; RECOMBINANT FUSION PROTEINS; RHEUMATIC DISEASES;

EID: 77957788567     PISSN: 03401855     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00393-009-0530-7     Document Type: Review

References (31)

1. Gabay C, Lamacchia C, Palmer G (2010) IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 6:232-241
2. Dinarello CA (2009) Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27:519-550
3. Franchi L, Eigenbrod T, Munoz-Planillo R, Nunez G (2009) The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol 10:241-247
4. Genovese MC, Cohen S, Moreland L et al (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50:1412-1419
5. Fleischmann RM, Schechtman J, Bennett R et al (2003) Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum 48:927-934
6. Lequerre T, Vittecoq O, Loet X le (2007) What is the role for interleukin-1 receptor antagonist in rheumatic disease? Joint Bone Spine 74:223-226
7. Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 36:1118-1125
8. Singh JA, Christensen R, Wells GA et al (2010) Biologics for rheumatoid arthritis: an overview of Cochrane reviews (Review). The Cochrane Library
9. Dinarello CA (2010) Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 29:317-329
10. Dinarello CA (2010) IL-1: discoveries, controversies and future directions. Eur J Immunol 40:599-606
11. Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev: CD005121
12. Manger B, Gaubitz M, Michels H (2009) Recommendations on therapy using interleukin-1beta-blocking agents. Z Rheumatol 68:766-771
13. Wollenhaupt JAR, Backhaus M, Baerwald C et al (2009) Aktualisiertes Therapieschema der Rheumatoiden Arthritis. Ergebnisse eines Konsensusprozesses deutscher Rheumatologen 2009. Aktuelle Rheumatologie 34:234-239
14. Smolen JS, Landewe R, Breedveld FC et al (2010) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 69:964-975
15. Kotter I, Schedel J, Kummerle-Deschner JB (2009) Periodic fever syndrome/autoinflammatory syndrome. Z Rheumatol 68:137-148
16. Alten R, Gram H, Joosten LA et al (2008) The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 10:R67
17. Quartier P, Allantaz, F, Cimaz, R et al (2008) A multicentric, double-blind trial of anakinra versus placebo in systemic-onset juvenile idiopathic arthritis (ANAJIS trial): efficacy and tolerance over 12 months. Arthritis Rheum 58:S632
18. Lequerre T, Quartier P, Rosellini D et al (2008) Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 67:302-308
19. Lovell DJ, Gianinni EH, Kimura Y et al (2006) Preliminary evidence for bioactivity of IL-1 trap (Rilonacept), a long acting Il-1 inhibitor, in systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum 54:S325
20. Ruperto N, Quartier P, Wulfraat N et al (2009) for PRINTO. Evaluation of safety and preliminary efficacy of canakinumab (ACZ885), a new IL-1-beta blocking monoclonal antibody, in children with systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum 60:S2055
21. Hoffman HM, Throne ML, Amar NJ et al (2008) Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 58:2443-2452
22. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB et al (2009) Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 360:2416-2425
23. Gattorno M, Pelagatti MA, Meini A et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58:1516-1520
24. Pavelka K (2002) Clinical effects of prainacasan (PRAL), an orally-active interleukin-1β converting enzyme (ICE) inhibitor, in a 285 patient phase II trial in rheumatoid arthritis (abstract LB02). Arthritis Rheum 46:3415
25. Alpay N, Sumnu A, Caliskan Y et al (2010) Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int [Epub ahead of print]
26. Naumann L, Feist E, Natusch A et al (2010) IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis 69:466-467
27. Kotter I, Wacker A, Koch S et al (2007) Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. Semin Arthritis Rheum 37:189-197
28. Pope RM, Tschopp J (2007) The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 56:3183-3188
29. Bacconnier L, Jorgensen C, Fabre S (2009) Erosive osteoarthritis of the hand: clinical experience with anakinra. Ann Rheum Dis 68:1078-1079
30. Larsen CM, Faulenbach M, Vaag A et al (2007) Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:1517-1526
31. Colina M, Pizzirani C, Khodeir M et al (2010) Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. Rheumatology (Oxford) 49:1416-1418